Table 5.

Standardized prevalence ratios for malignancy in the IgG4-RD cohort compared to the US general population^*

Sex, age (years)	No. of IgG4-RD cases	Observed malignancies	Cohort prevalence	US prevalence	Expected malignancies
Men and women combined
20–29	6	0	0	0.003	0.02
30–39	13	1	0.08	0.008	0.1
40–49	22	2	0.09	0.02	0.4
50–59	32	4	0.13	0.04	1.4
60–69	33	5	0.2	0.09	3.1
70–79	16	6	0.4	0.2	2.5
80–89	3	2	0.7	0.2	0.5
Total		20 (95% CI 11.2–28.8)			8.0 (SPR 2.51 [95% CI 1.14–3.61])
Men
20–29	2	0	0	0.003	0.006
30–39	7	1	0.1	0.006	0.04
40–49	13	1	0.08	0.01	0.2
50–59	20	3	0.2	0.04	0.7
60–69	21	4	0.2	0.1	2.1
70–79	10	4	0.4	0.2	2.0
80–89	3	2	0.7	0.3	0.8
Total		15 (95% CI 11.1–18.9)			5.8 (SPR 2.60 [95% CI 1.93–3.27])
Women
20–29	4	0	0	0.003	0.01
30–39	6	0	0	0.01	0.06
40–49	9	1	0.1	0.02	0.2
50–59	12	1	0.08	0.05	0.6
60–69	12	1	0.08	0.09	1.0
70–79	6	2	0.3	0.1	0.7
Total		5 (95% CI 2.8–7.2)			2.6 (SPR 1.89 [95% CI 1.05–2.74])

^*IgG4-RD = IgG4-related disease; 95% CI = 95% confidence interval; SPR = standardized prevalence ratio.